You call the shots

Details

• Alternative Title:
  Intramuscular Shingrix vaccination infographic
• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.)
• Description:
  Recombinant Zoster Vaccine (Shingrix) ; Using Shingrix vaccine ; KNOW THE SITE. GET IT RIGHT! ; Store and Prepare the Vaccine ; • Store Shingrix vaccine (recombinant zoster vaccine) AND adjuvanted diluent in the refrigerator between 2°C and 8°C (36°F and 46°F). ; • Store in original packaging, protected from light. ; • DO NOT FREEZE. Frozen vaccine or adjuvanted diluent should NOT be administered. ; • Prepare vaccine just before administration using a new, sterile needle and syringe. ; • Reconstitute vaccine with the adjuvanted diluent that came with the lyophilized vaccine. ; IM injection best practices ; • Identify the site carefully using anatomical landmarks. Shoulder injury related to vaccine administration (SIRVA) may result from the unintentional injection of a vaccine into tissues and structures lying underneath the deltoid muscle. ; • Administering the injection too high on the upper arm may cause shoulder injury. ; Administer the vaccine correctly ; • Route: Intramuscular (IM) injection ; • Needle: 23-25 gauge, 1 to 1 1/2 inch sterile needle ; • Dose: 5 mL ; • Site: Deltoid muscle ; • Administration: May administer during the same clinical visit as other needed vaccines. Administer in a separate limb from other vaccines, if possible. ; Follow the schedule ; • CDC recommends Shingrix as preferred over Zostavax® (zoster vaccine live) for the prevention of herpes zoster (shingles) and related complications.* ; • Shingrix vaccine is a 2-dose series, administered 2 to 6 months apart. Both doses are needed to provide protection. ; • Shingrix is recommended for individuals 50 years of age and older. ; • Shingrix can be administered to people who have received Zostavax or have already had shingles. ; • If Zostavax was previously given, wait at least 8 weeks before administering Shingrix. ; • Schedule an appointment for the second dose before the patient leaves. ; Educate the patient ; • About 1 out of 6 people who got Shingrix experienced side effects that prevented them from doing regular activities for a few days. ; • Remind patients they may experience a local reaction or side effect such as pain, redness, and swelling and systemic reactions such as myalgia, fatigue, and headache that may interrupt regular activities a few days after receiving Shingrix. ; • It is important patients get the second dose of Shingrix to build strong protection against shingles, even if they have side effects from the first dose. ; • Patients’ reactions to each dose may be different; just because they have a reaction to the first dose does not mean they will have a reaction to the second. ; For additional information on proper vaccine administration, visit the CDC vaccine administration web page at https://www.cdc.gov/vaccines/hcp/admin/admin-protocols.html ; *Zostavax® is still recommended for healthy adults 60 years and older. Learn more about Zostavax https://www.cdc.gov/vaccines/vpd/shingles/public/zostavax/index.html. ; Report any clinically significant adverse event after vaccination to the Vaccine Adverse Event Reporting System (VAERS) at vaers.hhs.gov ; U.S. Department of Health and Human Services, Centers for Disease Control and Prevention ; CS249275-BE ; Called also: Intramuscular Shingrix vaccination infographic ; call-the-shots-Shingrix-P_508.pdf ; Publication date from document properties.
  More +
• Subjects:
  • Adult
  • Herpes Zoster
  • Herpes Zoster Vaccine
  • Injections, Intramuscular
• Document Type:
  Poster
• Genre:
  Infographic
• Pages in Document:
  1 infographic
• Download URL:
  https://stacks.cdc.gov/view/cdc/56362/cdc_56362_DS1.pdf
• File Type:
  [PDF - 264.35 KB]
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:b2d9c132e969c2ff6a2c295072cc27293e7afa4fad1369cfdc683ca1f83d8702